6 mg/ml
Sponsors
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy, Swiss Group for Clinical Cancer Research, NSABP Foundation Inc., Iperboreal Pharma S.r.l., Rheinische Friedrich-Wilhelms-Universitaet Bonn
Conditions
Advanced throat and larynx cancerCystic FibrosisEnd-Stage Kidney DiseaseHER2 negative breast cancerN2)Patients with early breast cancerResectablelocally advanced non-small cell lung cancer (NSCLC
Phase 2
A phase II study of preoperative stereotactic radiation therapy boost combined with short-course immunotherapy (pembrolizumab versus placebo, randomized, double-blind) and standard chemotherapy in patients with newly diagnosed HER2-negative non-metastatic breast cancer with lack of early metabolic response in 18-fluorodeoxyglucoseFDG-PET/CT after 1st chemoterapy cycle
RecruitingCTIS2023-504145-31-00
Start: 2024-06-10Target: 78Updated: 2024-02-21
Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III(N2) non-small cell lung cancer (NSCLC). A multicenter phase II trial.
Active, not recruitingCTIS2023-504536-18-00
Start: 2024-07-31Target: 10Updated: 2025-10-22
A phase II trial to assess the activity and tolerability of Thymosin alpha 1 in Cystic Fibrosis Patients
CompletedCTIS2024-518102-41-00
Start: 2021-12-07End: 2025-03-07Target: 24Updated: 2025-02-18
The asssessment of the efficacy of induction radiochemotherapy using low doses of ionizing radiation (iCHRTL) in the treatment of patients with advanced throat and larynx cancer
RecruitingCTIS2024-517480-23-00
Start: 2022-02-17Target: 40Updated: 2025-01-31
Prospective randomized Phase II trial on Induction Immunochemotherapy followed by surgery or definitive chemoradiation and consolidation Durvalumab (MEDI4736) in resectable and borderline resectable stage IIIA/B NSCLC
RecruitingCTIS2024-516367-80-00
Start: 2025-04-24Target: 176Updated: 2025-10-10
Phase 3
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo "GeparDouze"
CompletedCTIS2023-508472-11-00
Start: 2018-06-13End: 2025-11-19Target: 978Updated: 2025-08-05
A Study to Evaluate the Efficacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis (ELIXIR)
Active, not recruitingCTIS2024-513562-19-00
Start: 2023-04-21Target: 155Updated: 2025-05-19